21
Abstract Views
4
PDF Download
Clinical Chemistry

Diagnostic role of end-tidal carbon dioxide in differentiating chronic obstructive pulmonary disease and chronic heart failure: Association with NT-proBNP in dyspneic patients

Mustafa Erkan Yalova Training and Research Hospital, Turkey Correspondence drmustafaerkan@gmail.com
,
Oguzhan Bol Kayseri City Training and Research Hospital, Turkey Correspondence bologuzhan@gmail.com
,
Nursah Basol Yalova University Faculty of Medicine, Department of Emergency Medicine, Turkey Correspondence drnursahbs@hotmail.com
Pages 139-148
Browse this journal

Abstract

Chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD) are increasingly prevalent among the elderly, and both frequently present with dyspnea as the primary symptom in emergency departments. Differentiating between the two conditions remains challenging, particularly in primary care, yet is essential given their distinct management approaches and prognostic implications. This study investigated the diagnostic utility of non-invasive end-tidal carbon dioxide (ETCO?) measurements in patients presenting with dyspnea and assessed whether combining ETCO? with N-terminal pro-brain natriuretic peptide (NT-proBNP) enhances diagnostic accuracy. A total of 205 patients admitted to the Emergency Department of Kayseri City Hospital and subsequently diagnosed with either CHF or COPD were included. Demographic data, clinical history, treatments, vital signs, NT-proBNP levels, echocardiographic findings, arterial blood gas results, integrated pulmonary index (IPI) scores, ETCO? values, and clinical outcomes were recorded. Echocardiography was performed by a cardiologist, and ETCO? and IPI values were obtained using the Medtronic Capnostream™ 35 monitor. NT-proBNP (p <0.001), ETCO? (p <0.001), and IPI (p = 0.038) were all statistically significant in differentiating CHF from COPD, with ETCO? demonstrating the strongest association. The addition of NT-proBNP or IPI to ETCO? did not provide further diagnostic benefit. NT-proBNP was also predictive of hospital admission (p <0.001). These findings indicate that quantitative ETCO? measurement, performed with a non-invasive and patient-friendly sidestream technique, is effective for diagnostic differentiation in acute dyspnea and has strong clinical applicability. ETCO? outperformed both NT-proBNP and IPI, and its use alone may be sufficient in this setting. Higher NT-proBNP cut-off values may be more appropriate in acute-onset dyspnea, and elevated NT-proBNP in COPD patients may hold prognostic value for poorer clinical outcomes.

There is no Figure or data content available for this article

References

  • 1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39. doi:10.1093/eurheartj/ehad195
  • 2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the prevention, diagnosis, and management of COPD: 2024 report. 2024. Available from: https://goldcopd.org
  • 3. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25.
  • 4. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
  • 5. Cinar O, Acar YA, Arziman I, Kilic E, Eyi YE, Ocal R. Can mainstream end-tidal carbon dioxide measurement accurately predict the arterial carbon dioxide level of patients with acute dyspnea in ED? Am J Emerg Med. 2012;30(2):358–61.
  • 6. Brown RH, Brooker A, Wise RA, Reynolds C, Loccioni C, Russo A, et al. Forced expiratory capnography and chronic obstructive pulmonary disease (COPD). J Breath Res. 2013;7(1):016006.
  • 7. Santus P, Radovanovic D, Saad M, Perrone T, Beretta E, Savino K, et al. Acute dyspnea in the emergency department: a clinical review. Intern Emerg Med. 2023;18(6):1491–1507. doi:10.1007/s11739-023-03322-8
  • 8. Martindale JL, Wakai A, Collins SP, Levy PD, Diercks D, Hiestand BC, Fermann GJ, deSouza I, Sinert R. Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis. Acad Emerg Med. 2016 Mar;23(3):223-42. doi: 10.1111/acem.12878. Epub 2016 Feb 13. PMID: 26910112.
  • 9. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–9.
  • 10. Dunlay SM, Roger VL. Understanding the epidemic of heart failure: Past, present, and future. Curr Heart Fail Rep. 2014;11(4):404–15.
  • 11. Ostoji? J, Pintari? H. Chronic Obstructive Pulmonary Disease and Heart Failure: Closer than Close. Acta Clin Croat. 2017 Jun;56(2):269-276. doi: 10.20471/acc.2017.56.02.10. PMID: 29485794.
  • 12. Pahal P, Hashmi MF, Sharma S. Chronic Obstructive Pulmonary Disease Compensatory Measures. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK525962/
  • 13. Tyagi D, Govindagoudar MB, Jakka S, Chandra S, Chaudhry D. Correlation of PaCO2 and ETCO2 in COPD Patients with Exacerbation on Mechanical Ventilation. Indian J Crit Care Med. 2021 Mar;25(3):305-309. doi: 10.5005/jp-journals-10071-23762. PMID: 33790512; PMCID: PMC7991761
  • 14. Brown LH, Gough JE, Seim RH. Can quantitative capnometry differentiate between cardiac and obstructive causes of respiratory distress? Chest. 1998;113(2):323–6.
  • 15. Klemen P, Golub M, Grmec S. Combination of quantitative capnometry, N-terminal pro-brain natriuretic peptide, and clinical assessment in differentiating acute heart failure from pulmonary disease as cause of acute dyspnea in pre-hospital emergency setting: A diagnostic study. Croat Med J. 2009;50(2):133–42.
  • 16. Grmec S, Golub M, Klemen P, ?ander D. Utility of the quantitative capnometry and rapid bedside test for N-terminal pro-brain natriuretic peptide in the evaluation of respiratory distress in prehospital setting: Preliminary results. J Emerg Med. 2007;33(3):322–9.
  • 17. Su X, Lei T, Yu H, Zhang L, Feng Z, Shuai T, Guo H, Liu J. NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2023 May 10;18:811-825. doi: 10.2147/COPD.S396663. PMID: 37197601; PMCID: PMC10183357.
  • 18. Chi SY, Kim EY, Ban HJ, Oh IJ, Kwon YS, Kim KS, Kim YI, Kim YC, Lim SC. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung. 2012 Jun;190(3):271-6. doi: 10.1007/s00408-011-9363-7. Epub 2012 Jan 14. PMID: 22246552; PMCID: PMC3339052.
  • 19. Ozdemirel TS, Ula?li SS, Yeti? B, et al. Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD: an observational study. Anadolu Kardiyol Derg. 2014;14(4):370–377.
  • 20. Michael FA, Peveling-Oberhag J, Herrmann E, Zeuzem S, Bojunga J, Friedrich-Rust M. Evaluation of the Integrated Pulmonary Index® during non-anesthesiologist sedation for percutaneous endoscopic gastrostomy. J Clin Monit Comput. 2021 Oct;35(5):1085-1092. doi: 10.1007/s10877-020-00563-2. Epub 2020 Jul 30. PMID: 32734356; PMCID: PMC8497449.
  • 21. Karaarslan FN, Öztürk ZS, I??k GÇ, Çevik Y. Value of integrated pulmonary index to predict exacerbation of chronic obstructive pulmonary Disease's severity. Am J Emerg Med. 2023 Sep;71:54-58. doi: 10.1016/j.ajem.2023.05.043. Epub 2023 Jun 8. PMID: 37331230.
  • 22. Karakilic E, Kepez A, Abali G, Coskun F, Kunt M, Tokgözoglu L. The relationship between B-type natriuretic peptide levels and echocardiographic parameters in patients with heart failure admitted to the emergency department. Anadolu Kardiyol Derg. 2010;10(2):143–9.
  • 23. Adrish M, Nannaka VB, Cano EJ, Bajantri B, Diaz-Fuentes G. Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction. Int J Chron Obstruct Pulmon Dis. 2017;12:1183–9.
  • 24. Rubinsztajn R, Nasi?owski J, Przyby?owski T, Karwat K, Chazan R. Usefulness of NT-proBNP serum level in the diagnosis of dyspnea in COPD patients. Adv Respir Med. 2013;81(1):24–9.
  • 25. van Gestel YR, Goei D, Hoeks SE, Sin DD, Flu WJ, Stam H, Mertens FW, Bax JJ, van Domburg RT, Poldermans D. Predictive value of NT-proBNP in vascular surgery patients with COPD and normal left ventricular systolic function. COPD. 2010 Feb;7(1):70-5. doi: 10.3109/15412550903499472. PMID: 20214466.
  • 26. Berthelot E, Bailly MT, Lehova XC, Rahmani MEB, Bounab R, Mewton N, Dobbs JE, Mas R, Frank M, Lellouche N, Paclot M, Jourdain P. Determination of optimal NT-proBNP and BNP thresholds for the diagnosis of heart failure in patients over 75 years old. ESC Heart Fail. 2024 Oct;11(5):3232-3241. doi:10.1002/ehf2.14894. Epub 2024 Jun 24. PMID: 38923835; PMCID: PMC11424345.
  • 27. C J Taylor, K S Taylor, J M Ordonez-Mena, N R Jones, A Bayes-Genis, F D R Hobbs, ESC Heart Failure Association age-adjusted natriuretic peptide thresholds for a new diagnosis of heart failure: diagnostic accuracy study, European Heart Journal, Volume 45, Issue Supplement_1, October 2024, ehae666.949, https://doi.org/10.1093/eurheartj/ehae666.949
  • 28. Suchina J, Lüthi-Corridori G, Jaun F, Leuppi JD, Boesing M. Diagnosis and Treatment of Acute Heart Failure: A Retrospective Observational Study and Medical Audit. J Clin Med. 2024 Oct 7;13(19):5951. doi: 10.3390/jcm13195951. PMID: 39408011; PMCID: PMC11478339.
  • 29. Ronen M, Weissbrod R, Overdyk FJ, Ajizian S. Smart respiratory monitoring: clinical development and validation of the IPI™ (Integrated Pulmonary Index) algorithm. J Clin Monit Comput. 2017 Apr;31(2):435-442. doi: 10.1007/s10877-016-9851-7. Epub 2016 Mar 9. PMID: 26961501; PMCID: PMC5346135.
There is no Supplemental content for this article.

How to Cite This

Erkan, M., Bol, O., & Basol, N. (2025). Diagnostic role of end-tidal carbon dioxide in differentiating chronic obstructive pulmonary disease and chronic heart failure: Association with NT-proBNP in dyspneic patients. Jurnal Teknologi Laboratorium, 14(2), 139–148. https://doi.org/10.29238/teknolabjournal.v14i2.596

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Verify authenticity via CrossMark

Copyright and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

  • BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability

All data generated during this study are included in this published article [and its supplementary information files].